BHC - Bausch Health Companies Inc.
| Previous close | 22.10 |
| Open | 21.88 |
| Bid | 21.12 x 1800 |
| Ask | 21.87 x 900 |
| Day's range | 21.25 - 22.13 |
| 52-week range | 17.20 - 28.45 |
| Volume | 2,141,237 |
| Avg. volume | 3,363,168 |
| Market cap | 7.521B |
| Beta (3Y monthly) | 2.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.61 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 2010-11-10 |
| 1y target est | 29.71 |
- Zacks
Is Bausch Health Cos (BHC) Outperforming Other Medical Stocks This Year?
Is (BHC) Outperforming Other Medical Stocks This Year?
- Zacks
Is Bausch Health Cos (BHC) a Good Value Investor Pick?
Let's see if Bausch Health Cos (BHC) stock is a good choice for value-oriented investors right now from multiple angles.
- Zacks
Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance
Aerie (AERI) lowers its annual sales guidance and reports a narrower loss in Q2.
- Zacks
Bausch (BHC) Misses on Q2 Earnings & Sales, Raises View
Bausch (BHC) misses on both earnings and sales in the second quarter of 2019 but lifts revenue outlook on new products.
Motley FoolBausch Health Companies Inc. (BHC) Q2 2019 Earnings Call Transcript
BHC earnings call for the period ending August 6, 2019.
- Market Realist
Bausch Health Raises Guidance, Shares Follow
Today, Bausch Health reported its second-quarter earnings results before the market opened. It reported revenue of $2.15 billion in the quarter.
- Motley Fool
Bausch Health Ups Its Full-Year Outlook After Posting Solid Organic Growth
The healthcare company reported especially strong sales growth in the second quarter for gastrointestinal drug Xifaxan.
- Simply Wall St.
Is Bausch Health Companies (NYSE:BHC) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- Zacks
Bausch Health (BHC) Misses Q2 Earnings and Revenue Estimates
Bausch (BHC) delivered earnings and revenue surprises of -2.83% and -0.69%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
What's in the Cards for Bausch Health (BHC) in Q2 Earnings?
Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q2 results on Aug 6.
- Zacks
Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Eton's Ophthalmic Solution Candidate Gets CRL, Shares Fall
Eton's (ETON) partner receives complete response letter for a regulatory application seeking approval of its pipeline candidate, EM-100, as a treatment for ocular itching.
- Zacks
Is Bausch Health (BHC) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Zacks
Aerie Completes Enrollment Under Rhopressa Study in Japan
Aerie (AERI) completes enrollment in mid-stage study on Rhopressa in Japan much ahead of schedule.
- Market Realist
Is Bausch Health Becoming a Successful Turnaround Story?
Bausch Health (BHC) has gained 20.13% in the last month and is up by 38.93% in 2019 on a YTD basis.
- Zacks
Bausch Gains 38.9% YTD on Product Launches & Debt Reduction
Bausch (BHC) is currently focusing on widening its ophthalmology and dermatology portfolio.
- Motley Fool
Why Shares of Bausch Health Companies Rocketed Higher in June
It was one of the best-performing healthcare stocks last month. Two new product launches and a big debt repayment were the primary contributors.
- Motley Fool
Here's Why Dova Pharmaceuticals Stock Jumped Higher Today
The drugmaker's Doptelet therapy just received an expanded approval.
- Zacks
Dova Receives Approval for Doptelet in Europe, Stock Up
Dova Pharmaceuticals (DOVA) announces approval of its thrombocytopenia drug, Doptelet, in Europe for patients with chronic liver disease.
- Zacks
Allergan Up As Analyst Statement Sparks Business Split Rumors
Allergan's (AGN) shares up following a conference call with one of the company's executives, which led an analyst to believe that a split of the company's business is in the cards.
- MarketWatch
Bausch Health to pay down more debt this week, stock rallies
Bausch Health Companies Inc. said Tuesday it will pay down an additional $100 million worth of debt this week, which will eliminate all mandatory amortization for the first quarter of 2020. The stock rose 1.9% in premarket trading. The maker of pharmaceutical, medical-device and over-the-counter products said it will use cash generated from operations to pay down the senior secured terms loans. The stock has lost 1.6% over the past three months but has rallied 28.6% year to date through Monday, while the S&P 500 has gained 17.5% this year.
- Barrons.com
Another Women’s Libido Drug, Vyleesi, Won FDA Approval. Stock Investors Aren’t Happy.
It has been a roller-coaster day on the market for the two companies behind Vyleesi, an injection that received Food and Drug Administration approval last week to treat low sex drive in women. The drug’s approval received significant news coverage, and much of it focused on the controversy that surrounded the other drug approved for low sex drive in women, Addyi, which has struggled on the market and drawn criticism for its potential side effects. The approval of Addyi, marketed by Sprout Pharmaceuticals, drew significant attention in 2015, and led to the $1 billion acquisition of Sprout by (BHC) now (BHC) (BHC).
- Zacks
Bausch Health (BHC) Catches Eye: Stock Jumps 6.2%
Bausch Health (BHC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
